48JPY
285.76 MJPY
1.30 BJPY
4.16 M
About HUMAN METABOLOME TECHNOLOGIES INC
Sector
Industry
Headquarters
Tsuruoka
Website
Employees (FY)
57
Founded
2003
ISIN
JP3794530000
FIGI
BBG005MQ74F4
Human Metabolome Technologies, Inc. engages in the business of diagnostic technology and medical products. Its operations are carried out through the following segments: Metabolome Analysis, Biomarker, and Temporary Staffing. The Metabolome Analysis segment provides contract analysis service based on the metabolome analysis on measured samples from the clients. The Biomarker segment deals with the development of biomarker license in collaboration with the group companies. The Temporary Staffing segment provides researchers and technicians. The company was founded by Yoshihiro Otaki, Masaru Tomita, and Tomoyoshi Soga on July 1, 2003 and is headquartered in Tsuruoka, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 6090 is 685.00 JPY — it has decreased by 0.72% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange HUMAN METABOLOME TECHNOLOGIES INC stocks are traded under the ticker 6090.
HUMAN METABOLOME TECHNOLOGIES INC is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
Yes, you can track HUMAN METABOLOME TECHNOLOGIES INC financials in yearly and quarterly reports right on TradingView.
Like other stocks, 6090 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HUMAN METABOLOME TECHNOLOGIES INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 57.00 employees. See our rating of the largest employees — is HUMAN METABOLOME TECHNOLOGIES INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HUMAN METABOLOME TECHNOLOGIES INC EBITDA is 280.41 M JPY, and current EBITDA margin is 22.43%. See more stats in HUMAN METABOLOME TECHNOLOGIES INC financial statements.